PT3436463T - Formas cristalinas de 2-[(2s)-1-azabiciclo[2.2.2]oct-2- il]-6-(3-metil-1h-pirazol-4-il)tieno[3,2-d]pirimidin-4(3h)- ona hemihidratada - Google Patents

Formas cristalinas de 2-[(2s)-1-azabiciclo[2.2.2]oct-2- il]-6-(3-metil-1h-pirazol-4-il)tieno[3,2-d]pirimidin-4(3h)- ona hemihidratada

Info

Publication number
PT3436463T
PT3436463T PT177190535T PT17719053T PT3436463T PT 3436463 T PT3436463 T PT 3436463T PT 177190535 T PT177190535 T PT 177190535T PT 17719053 T PT17719053 T PT 17719053T PT 3436463 T PT3436463 T PT 3436463T
Authority
PT
Portugal
Prior art keywords
hemihydrate
thieno
azabicyclo
pyrazol
pyrimidin
Prior art date
Application number
PT177190535T
Other languages
English (en)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT3436463T publication Critical patent/PT3436463T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
PT177190535T 2016-03-28 2017-03-27 Formas cristalinas de 2-[(2s)-1-azabiciclo[2.2.2]oct-2- il]-6-(3-metil-1h-pirazol-4-il)tieno[3,2-d]pirimidin-4(3h)- ona hemihidratada PT3436463T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314080P 2016-03-28 2016-03-28
US201662367842P 2016-07-28 2016-07-28

Publications (1)

Publication Number Publication Date
PT3436463T true PT3436463T (pt) 2021-09-06

Family

ID=58609973

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177190535T PT3436463T (pt) 2016-03-28 2017-03-27 Formas cristalinas de 2-[(2s)-1-azabiciclo[2.2.2]oct-2- il]-6-(3-metil-1h-pirazol-4-il)tieno[3,2-d]pirimidin-4(3h)- ona hemihidratada

Country Status (11)

Country Link
US (1) US11746109B2 (pt)
EP (1) EP3436463B1 (pt)
JP (2) JP6918824B2 (pt)
CN (1) CN108779126B (pt)
CA (1) CA3016708A1 (pt)
DK (1) DK3436463T3 (pt)
ES (1) ES2884398T3 (pt)
PL (1) PL3436463T3 (pt)
PT (1) PT3436463T (pt)
TW (1) TWI738748B (pt)
WO (1) WO2017172565A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
WO2017172565A1 (en) * 2016-03-28 2017-10-05 Takeda Pharmaceutical Company Limited Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate
CN112409373A (zh) * 2017-05-21 2021-02-26 南京正济医药研究有限公司 作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
IL310023A (en) 2017-06-21 2024-03-01 SHY Therapeutics LLC Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases
WO2019194319A1 (en) 2018-04-02 2019-10-10 Takeda Pharmaceutical Company Limited Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one
TW202016316A (zh) * 2018-06-19 2020-05-01 日商武田藥品工業股份有限公司 癌症治療方法
EP3823599A1 (en) 2018-07-19 2021-05-26 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor
WO2020239107A1 (zh) * 2019-05-30 2020-12-03 正大天晴药业集团股份有限公司 作为Cdc7抑制剂的四并环类化合物
BR112021026380A2 (pt) * 2019-06-24 2022-05-10 Naurex Inc Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidróxi-1-oxobutan-2-il)-1-oxo-2,5-diazaespiro[3.4]octano-5-carboxilato de terc-butila e métodos de preparação das mesmas
EP3999050A2 (en) 2019-07-19 2022-05-25 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
TW202227457A (zh) * 2020-11-30 2022-07-16 大陸商正大天晴藥業集團股份有限公司 作為Cdc7抑制劑的鹽型及其晶型
EP4288050A1 (en) 2021-02-08 2023-12-13 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602089A (en) * 2010-02-17 2014-05-30 Takeda Pharmaceutical Heterocyclic compounds having cell division cycle 7 inhibitory activity
WO2017172565A1 (en) * 2016-03-28 2017-10-05 Takeda Pharmaceutical Company Limited Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate

Also Published As

Publication number Publication date
PL3436463T3 (pl) 2021-11-08
ES2884398T3 (es) 2021-12-10
EP3436463B1 (en) 2021-06-23
CA3016708A1 (en) 2017-10-05
US20230102273A1 (en) 2023-03-30
JP6918824B2 (ja) 2021-08-11
DK3436463T3 (da) 2021-08-30
JP2020143076A (ja) 2020-09-10
WO2017172565A1 (en) 2017-10-05
CN108779126B (zh) 2021-07-16
JP2019510033A (ja) 2019-04-11
EP3436463A1 (en) 2019-02-06
US11746109B2 (en) 2023-09-05
TW201736383A (zh) 2017-10-16
CN108779126A (zh) 2018-11-09
TWI738748B (zh) 2021-09-11

Similar Documents

Publication Publication Date Title
PT3436463T (pt) Formas cristalinas de 2-[(2s)-1-azabiciclo[2.2.2]oct-2- il]-6-(3-metil-1h-pirazol-4-il)tieno[3,2-d]pirimidin-4(3h)- ona hemihidratada
IL266897B (en) History of thiano[2,3–d]pyrimidines for the treatment of viral infections
HK1245764A1 (zh) 3-取代的5-氨基-6h-噻唑並[4，5-d]嘧啶-2，7-二酮化合物
IL265757A (en) H1-Imidazo[5,4-b]pyridine-2(h3)-converted ions and their use as glun2b receptor modulators
HK1244804A1 (zh) 4h-吡咯並[3，2-c]吡啶-4-酮衍生物
HK1232223A1 (zh) 作為 抑制劑的 -氨基-吡啶並 嘧啶- -酮類衍生物及其用途
HK1257146A1 (zh) 新型的吡唑並[3，4-d]嘧啶化合物或其鹽
PL3379933T3 (pl) KOMPOZYCJE GRZYBOBÓJCZE ZAWIERAJĄCE POCHODNE 2,4-DIOKSO-1,4-DIHYDROTIENO[2,3-d]PIRYMIDYNY
HK1246792A1 (zh) 6，7-二氫吡唑並[1，5-a]吡嗪-4(5h)-酮化合物
HUE059274T2 (hu) Imidazo[4,5-d]pirrolo[2,3-b]piridin-származékok mint janus-kinázok inhibitorai
IL249706A0 (en) Thiano[3,2-d]pyrimidine, fluoro[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines are useful in the treatment of respiratory syncytial virus infections
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
HK1259613A1 (zh) 新型5h-吡咯並[2，3-d]嘧啶-6(7h)-酮衍生物
MA46937A (fr) 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones en tant qu'inhibiteurs de kinases dépendantes des cyclines
GB201802644D0 (en) Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
MX2018001350A (es) Procesos para preparar un inhibidor de fgfr.
IL267801B1 (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
HK1257427A1 (zh) 用於製備2-吡唑並[1，5-a]吡嗪-2-基吡啶並[1，2-a]嘧啶-4-酮的方法
IL265985A (en) Process for the preparation of (3s,4s)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3h-imidazo[4,5-c]pyridine-5(4h)-carboxylate
HUE050298T2 (hu) Pirazolo[3,4-D]pirimidin vegyületek vagy annak sói
ZA201702297B (en) A process for the preparation of 3-phenyl/heteroaryl-6-phenoxy-8-alkylamino-imidazo[1,2-b]pyridazine derivatives